198 related articles for article (PubMed ID: 33658617)
1. Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.
Díaz-Carballo D; Saka S; Acikelli AH; Homp E; Erwes J; Demmig R; Klein J; Schröer K; Malak S; D'Souza F; Noa-Bolaño A; Menze S; Pano E; Andrioff S; Teipel M; Dammann P; Klein D; Nasreen A; Tannapfel A; Grandi N; Tramontano E; Ochsenfarth C; Strumberg D
Commun Biol; 2021 Mar; 4(1):276. PubMed ID: 33658617
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment.
White CH; Beliakova-Bethell N; Lada SM; Breen MS; Hurst TP; Spina CA; Richman DD; Frater J; Magiorkinis G; Woelk CH
Front Immunol; 2018; 9():603. PubMed ID: 29706951
[TBL] [Abstract][Full Text] [Related]
3. Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency.
Hurst T; Pace M; Katzourakis A; Phillips R; Klenerman P; Frater J; Magiorkinis G
Retrovirology; 2016 Feb; 13():10. PubMed ID: 26852322
[TBL] [Abstract][Full Text] [Related]
4. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors.
Daskalakis M; Brocks D; Sheng YH; Islam MS; Ressnerova A; Assenov Y; Milde T; Oehme I; Witt O; Goyal A; Kühn A; Hartmann M; Weichenhan D; Jung M; Plass C
Cell Cycle; 2018; 17(7):811-822. PubMed ID: 29633898
[TBL] [Abstract][Full Text] [Related]
6. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase (HDAC) Inhibition Induces IκB Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Gatla HR; Zou Y; Uddin MM; Singha B; Bu P; Vancura A; Vancurova I
J Biol Chem; 2017 Mar; 292(12):5043-5054. PubMed ID: 28167529
[TBL] [Abstract][Full Text] [Related]
8. Human endogenous retrovirus HERV-K(HML-2) RNA causes neurodegeneration through Toll-like receptors.
Dembny P; Newman AG; Singh M; Hinz M; Szczepek M; Krüger C; Adalbert R; Dzaye O; Trimbuch T; Wallach T; Kleinau G; Derkow K; Richard BC; Schipke C; Scheidereit C; Stachelscheid H; Golenbock D; Peters O; Coleman M; Heppner FL; Scheerer P; Tarabykin V; Ruprecht K; Izsvák Z; Mayer J; Lehnardt S
JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271161
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
10. Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.
Butchi NB; Du M; Peterson KE
Glia; 2010 Apr; 58(6):650-64. PubMed ID: 19998480
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
12. Short Communication: The Broad-Spectrum Histone Deacetylase Inhibitors Vorinostat and Panobinostat Activate Latent HIV in CD4(+) T Cells In Part Through Phosphorylation of the T-Loop of the CDK9 Subunit of P-TEFb.
Jamaluddin MS; Hu PW; Jan Y; Siwak EB; Rice AP
AIDS Res Hum Retroviruses; 2016 Feb; 32(2):169-73. PubMed ID: 26727990
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
14. TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection.
Nazmi A; Mukherjee S; Kundu K; Dutta K; Mahadevan A; Shankar SK; Basu A
Neurobiol Dis; 2014 Sep; 69():235-47. PubMed ID: 24909816
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of histone deacetylase inhibitors.
Licciardi PV; Ververis K; Tang ML; El-Osta A; Karagiannis TC
Curr Mol Med; 2013 May; 13(4):640-7. PubMed ID: 23061676
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Miles MA; Harris MA; Hawkins CJ
Apoptosis; 2019 Jun; 24(5-6):404-413. PubMed ID: 30997620
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
20. Synergistic killing effect between vorinostat and target of CD146 in malignant cells.
Ma X; Liu J; Wu J; Yan X; Wu P; Liu Y; Li S; Tian Y; Cao Y; Chen G; Meng L; Xu G; Wang S; Lu Y; Ma D; Zhou J
Clin Cancer Res; 2010 Nov; 16(21):5165-76. PubMed ID: 20884621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
